In lung cancer, circulating lymphocytes with high-level PD-1, PD-L1, and PD-L2 expression are associated with poorer prognosis when treated with cytotoxics and tyrosine kinase inhibitors [133]. This evidence concerns the gene CD274 and lung carcinoma.